跳到正文
原文
Endpoints News 生物医药· Kyle LaHucik·· 2026-10-01AI 评分42

Kallyope 更名 TriGemX Bio 并获 9,400 万美元资金以推进偏头痛药物 III 期试验

Kallyope rebrands after Novo obesity deal, gets $94M for Phase 3 migraine drug

AI 导读

纽约市药物开发商 Kallyope 更名为 TriGemX Bio,宣布将业务重心完全转向偏头痛治疗。此举发生在与 Novo 达成肥胖症药物交易后,公司获得 9,400 万美元资金支持。该资金主要用于推进其在研偏头痛药物的 III 期临床试验。

正文

New York City drug de­vel­op­er Kally­ope is re­brand­ing as TriGemX Bio as it fo­cus­es sole­ly on treat­ing mi­graine.

To sup­port the re­struc­tured com­pa­ny and its …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

来源:Endpoints News 生物医药 · endpoints.news